Radioisotope Products and the Medicine of the Future: an IAEA Perspective

The production and application of radioisotopes and radiopharmaceuticals is a major peaceful application of nuclear science and technology and has opened new gateways for nuclear medicine in critical human diseases. Advances in the production of radioisotopes via nuclear reactors, accelerators, fission, etc. has facilitated the access to these products for Member States. 99Mo, 131I, 177Lu are among the most essential radioisotopes for nuclear medicine and human health and their production and availability always has been an important theme for professional societies and the International Atomic Energy Agency (IAEA). In the meantime, a large list of theranostic radioisotopes including but not limited to 89Zr, 68Ga, 225Ac, Cu-series, Sc-series, Tb-series etc. has provided a powerful toolbox for clinicians and the IAEA is taking steps to ensure their safe and appropriate application in radiopharmacy. The Agency promotes the production and application routes, including research reactors, cyclotrons, linear accelerators, and other cutting-edge methods, according to international and national guidelines and regulations. The IAEA also conducts activities such as Coordinated Research Projects (CRPs), Technical Meetings (TMs), national/regional training courses and conferences, to support and join forces with international professional societies in the development of human resources and research and development activities. Development of databases and freely available publications for all Member States are other useful means to support Member States in radiopharmaceutical sciences

Радиоизотопные препараты и медицина будущего: взгляд МАГАТЭ

The production and application of radioisotopes and radiopharmaceuticals is a major peaceful application of nuclear science and technology and has opened new gateways for nuclear medicine in critical human diseases. Advances in the production of radioisotopes via nuclear reactors, accelerators, fission, etc. has facilitated the access to these products for Member States. 99Mo, 131I, 177Lu are among the most essential radioisotopes for nuclear medicine and human health and their production and availability always has been an important theme for professional societies and the International Atomic Energy Agency (IAEA). In the meantime, a large list of theranostic radioisotopes including but not limited to 89Zr, 68Ga, 225Ac, Cu-series, Sc-series, Tb-series etc. has provided a powerful toolbox for clinicians and the IAEA is taking steps to ensure their safe and appropriate application in radiopharmacy. The Agency promotes the production and application routes, including research reactors, cyclotrons, linear accelerators, and other cutting-edge methods, according to international and national guidelines and regulations. The IAEA also conducts activities such as Coordinated Research Projects (CRPs), Technical Meetings (TMs), national/regional training courses and conferences, to support and join forces with international professional societies in the development of human resources and research and development activities. Development of databases and freely available publications for all Member States are other useful means to support Member States in radiopharmaceutical sciences.Производство и применение радионуклидов и радиофармацевтических препаратов — яркий пример использования ядерной науки и технологии в мирных целях, для терапии серьезных заболеваний. Достижения в области производства радиоизотопов с помощью ядерных реакторов, ускорителей, деления и т.д. упростили для государств, входящих в Международное агентство по атомной энергии (МАГАТЭ), доступ к радиоизотопным препаратам. 99Mo, 131I, 177Lu являются одними из наиболее важных радиоизотопов для ядерной медицины и здравоохранения, и их производство и доступность всегда были важной темой обсуждений внутри профессиональных сообществ и МАГАТЭ. Тераностические радиоизотопы, в том числе 89Zr, 68Ga, 225Ac, Cu-серию, Sc-серию, Tb-серию и т. д., также имеют большой потенциал использования в клинической практике, и МАГАТЭ предпринимает меры для обеспечения их безопасного и надлежащего применения в радиофармацевтике. МАГАТЭ создает условия для использования передовых методов и технологий, таких как исследовательские реакторы, циклотроны, линейные ускорители и др., в производстве и применении радиоизотопов в соответствии с международными и национальными руководствами и нормами. МАГАТЭ организует и проводит совместные исследования, технические совещания, национальные/региональные учебные курсы и конференции в целях поддержки международных профессиональных сообществ и объединения усилий для развития кадрового потенциала и научно-исследовательской деятельности. Эффективными способами поддержки радиофармацевтической науки также являются разработка баз данных и обеспечение открытого доступа к научным публикациям для всех государств-членов

Measurement of the Zγ production cross section in pp collisions at 8 TeV and search for anomalous triple gauge boson couplings

Open Access, Copyright CERN, for the benefit of the CMS Collaboration. Article funded by SCOAP3.Abstract: The cross section for the production of Zγ in proton-proton collisions at 8 TeV is measured based on data collected by the CMS experiment at the LHC corresponding to an integrated luminosity of 19.5 fb−1. Events with an oppositely-charged pair of muons or electrons together with an isolated photon are selected. The differential cross section as a function of the photon transverse momentum is measured inclusively and exclusively, where the exclusive selection applies a veto on central jets. The observed cross sections are compatible with the expectations of next-to-next-to-leading-order quantum chromodynamics. Limits on anomalous triple gauge couplings of ZZγ and Zγγ are set that improve on previous experimental results obtained with the charged lepton decay modes of the Z boson

Search for lepton-flavour-violating decays of the Higgs boson

Peer reviewe

Search for neutral resonances decaying into a Z boson and a pair of b jets or tau leptons

Peer reviewe

Study of gels of molybdenum with cerium in the preparation of generators of 99Mo - 99mTc

99mTc has ideal nuclear properties for organ imaging in nuclear medicine, and it is obtained from the 99Mo-99mTc generator. Four different types of generators are available: chromatographic that uses 99Mo from fission of uranium; MEK solvent extraction; Tc2O7 sublimation; gel chromatographic. This work presents the preparation of gel generators of molybdenum with cerium and characterization of the gels: mass ratio between molybdenum and cerium, structure, size of particles and elution percentage of 99mTc after irradiating the gels. Eight gels were prepared at the same temperature of 50 ºC with concentrations of NaOH of 2 and 4 mol/L, mass ratio of 0.31 and 0.38 and final pH of 3.5 and 4.5. The analysis of the results proved that these gels are not adequate for preparation of the generators of 99Mo-99mTc, since the elution percentages are low, when compared with the gel of molybdenum with zirconium.<br>O 99mTc é o radiofármaco mais utilizado em Medicina Nuclear. Ele é obtido do gerador de 99Mo-99mTc e existem quatro tipos diferentes de geradores: cromatográfico que utiliza 99Mo de fissão; extração por solvente com MKT; sublimação do heptaóxido de tecnécio; cromatográfico tipo gel. Este trabalho apresenta a preparação de geradores tipo gel de molibdênio com cério, a caracterização desses géis com relação à quantidade de molibdênio e de cério, sua estrutura, tamanho das partículas e porcentagem de eluição do 99mTc após o gel ser irradiado. Foram preparados oito géis na temperatura de 50ºC com concentração de NaOH de 2 e 4 mol/L, relação de massa de 0,31 e 0,38 e pH final de 3,5 e 4,5. A análise dos resultados comprovou que esses géis não são adequados para preparação dos geradores de 99Mo-99mTc, já que as porcentagens de eluição são baixas, quando comparadas com o gel de molibdênio com zircônio

Therapeutic Radiopharmaceuticals Labelled with Copper-67, Rhenium-186 and Scandium-47 (IAEA-TECDOC-1945)

Theranostic radiopharmaceuticals have shown tremendous capabilities in the last decade in the treatment and diagnosis of human diseases via nuclear medicine procedures. In particular, the use of radiometals has experienced a great increase as a result of the development of relevant production technologies. This publication presents the outcome of an IAEA coordinated research project (CRP) focusing on the production, quality control and radiopharmaceutical aspects of three key radionuclides, 67CU, 186Re and 47Sc, which have been selected based on their theranostic potential and their dual production routes. The publication was compiled using inputs from experts in the field as well as presenting the overall results of the CRP. It contains separate sections for each radionuclide including: nuclear data and information on targetry, irradiation, chemical separation, quality control as well as sample radiopharmaceutical production. The findings and considerations will be of use to scientists and technologists interested in translating research reactor and cyclotron based radioisotope production into practice, as well as to post graduate students in the field

The mystery of recent stratospheric temperature trends

A new data set of middle- and upper-stratospheric temperatures based on reprocessing of satellite radiances provides a view of stratospheric climate change during the period 1979–2005 that is strikingly different from that provided by earlier data sets. The new data call into question our understanding of observed stratospheric temperature trends and our ability to test simulations of the stratospheric response to emissions of greenhouse gases and ozone-depleting substances. Here we highlight the important issues raised by the new data and suggest how the climate science community can resolve them